Baxter International agreed to buy German biopharmaceutical company SuppreMol for about €200 million, in a move to improve its portfolio of autoimmune treatments.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 03/04/2015 - 7:45am
Baxter International agreed to buy German biopharmaceutical company SuppreMol for about €200 million, in a move to improve its portfolio of autoimmune treatments.